Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.

The study utilized "interruption-free survival" as a primary endpoint, a pragmatic measure derived from real-world data. This serves as a valuable surrogate for treatment toxicity, as clinicians typically pause treatment in response to adverse events, providing a quantifiable measure of a drug's real-world tolerability.

Comparing elacestrant (EMERALD) and imlunestrant (EMBER-3) is flawed because the patient populations were fundamentally different. EMERALD's patients were more heavily pretreated, a fact starkly illustrated by the standard-of-care arms' median Progression-Free Survival of 1.9 months versus 3.8 months in EMBER-3.

The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.

Real-world data for pemigatinib in cholangiocarcinoma showed a higher response rate (59%) than the pivotal FITE-202 trial (36%). This discrepancy likely stems from the lack of standardized, centrally reviewed imaging in real-world settings, which can inflate perceived response. Comparable progression-free survival across both settings supports this interpretation.

While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.

Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.

Contrary to the norm where real-world outcomes are worse than in controlled trials, real-world data for the oral SERD elacestrant shows efficacy as good as, or even better than, the pivotal EMERALD study. This unusual finding significantly bolsters confidence in the drug's broad clinical utility across a less-selected patient population.

Large real-world databases show elacestrant monotherapy achieves a median time-to-next-treatment of over 8 months. This impressive outcome aligns with the most favorable subgroup from the pivotal EMERALD trial (patients on prior CDK4/6i >12 months), suggesting that clinicians are successfully identifying the ideal candidates for this therapy in routine practice.